Immunomodulatory Treatment In Patients With Severe Pneumonia COVID-19

Clinical trial to perform immunomodulatory treatment in adult patients with severe COVID-19 pneumonia with the aim of helping to define the standard treatment for this disease


Description of the Study:

  • Title: Randomised, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs.
  • Principal Investigator: Salvador Augustin.
  • Centres of Implementation: Hospital Universitari Vall d’Hebron.
  • Study Population: 290 individuals aged 18-80 years with severe COVID-19 pneumonia.
  • Study Type: Randomised, controlled, open, one-site clinical trial.
  • Methods: The drugs to be evaluated in this trial are:
    – Sandimmun concentrate for solution for infusion (intravenous route), the active substance of which is Cyclosporine.
    – Sandimmun soft capsule (oral route), the active substance of which is Cyclosporine.
    – Roactemra concentrate for solution for infusion (intravenous route), the active substance of which is Tocilizumab.

Objectives of the Study:

Principal Objective: To assess the mortality impact at 28 days of an immunomodulatory strategy with 2 treatment regimens stratified according to IL-6 plasma levels, administered in addition to standard treatment, in adult patients with severe COVID-19 pneumonia.

Secondary Objective: To assess the impact of this strategy on the following variables: premature mortality (48 hours, 7 days and at hospital), mortality at intensive care unit, days of mechanical ventilation, virus clearance (viral clearance / viral shedding), time to normalization of oxygen saturation , time to defervescence (fever reduction), improvement of inflammatory reaction, days of hospitalization, days of intubation, safety and tolerability of the intervention

More about this Study:

Rationale: The aim is to study the response of patients with severe COVID-19 pneumonia to an immunomodulatory strategy with 2 treatment regimens stratified according to plasma IL-6 levels administered in addition to standard treatment aimed at reducing the inflammatory/immunological response and obtaining a therapeutic benefit in these patients. Positive results could help define the standard treatment of severe COVID-19 pneumonia and have a dramatic impact on both local and global morbidity and mortality. Negative results would also constitute useful scientific evidence to abandon unsubstantiated empirical approaches and help redirect/prioritise resources and efforts in other more promising directions.

Hospital Vall D Hebron 1


Other Studies about Pharmacology:

ANTICOV Study : COVID-19 en Afrique

Collaborez avec l’étude ANTICOV et contribuez à traiter la COVID-19 en Afrique.

Progestérone pour traiter le COVID-19

Est-ce que les hormones sexuelles peuvent aider les hommes survivre le COVID-19 ? Cette étude a pour objectif évaluer la sécurité et l’efficacité de la progestérone dans le traitement de COVID-19 chez les hommes hospitalisés.

Flower 729514 1920

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.

CIBERESUCI COVID

CIBERES UCI COVID is a fundamental study that will improve care of critical patients infected by COVID-19.

Vaccination In People With Long COVID

This study aims to determine the effects of vaccination against SARS-CoV-2 in people with long COVID.

Antibiotic prescription during the COVID-19 pandemic

Antimicrobial stewardship approaches urgently need to be reinforced during the COVID-19 pandemic. This study evaluates the impact of the COVID-19 on antibiotic consumption.

Antihistamines and azithromycin as a treatment for COVID-19

This study suggests that primary care diagnosis and treatment with antihistamines, plus azithromycin in selected cases, may treat COVID-19 and prevent progression to severe disease in elderly patients.

Real-life Use Of Remdesivir In Hospitalized Patients With COVID-19

This study aims to evaluate in clinical practice the efficacy and safety of remdesivir in patients admitted for COVID-19.

Prevention With Calcifediol Of Respiratory Problems Caused By COVID-19

This multicentre clinical trial aims to demonstrate that treatment with Calcifediol reduces the need for invasive ventilation and Intensive Care Unit admissions and deaths.

Maraviroc in patients hospitalized for COVID-19

Phase II clinical trial evaluating the safety and efficacy of the drug Maraviroc combined with standard therapy versus standard therapy in patients infected with SARS-CoV-2 and hospitalised with COVID-19.